One year of treatment with either of two strong blood-thinning medications—ticagrelor and prasugrel—by people with type 1 or type 2 diabetes who had a drug-eluting stent placed in their heart to treat coronary artery blockages did not offer the same level of benefit to prevent stent clotting, heart attacks, and bleeding complications, according to findings presented during a preliminary late-breaking science session during the American Heart Association’s Scientific Sessions 2025 in New Orleans on November 10.